We studied premature atherosclerosis with carotid Doppler ultrasonography in active acromegaly before and after treatment. Patients (n = 27) with active acromegaly and 12 age-, gender-, and body mass index-matched healthy individuals were included in the study. Carotid intima–media thickness was decreased significantly in the inactive group after treatment (median: 0.6 mm, interquartile range [IQR]: 0.55-0.80]) when compared with the active group (median: 0.9 mm [IQR: 0.75-1.15], P < .0001), but there was no significant difference between the inactive and control groups. There was a correlation between homeostasis model of assessment–insulin resistance (P = .01, r = .41) and growth hormone (GH; P < .0001, r = .46). In conclusion, premature atherosclerosis was demonstrated in active acromegaly patients probably as a consequence of insulin resistance and direct vascular effects of GH and/or insulin-like growth factor 1.
OrmeSMMcNallyJQCartwrightRABelchetsPE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab. 1998;83(8):2730–2734.
2.
ColaoABaldelliRMarzulloP. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab. 2000;85(1):193–199.
3.
SowersJRStandleyPRRamJLJacoberSSimpsonLRoseK. Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hypertens. 1993;6(7 pt 2):260–270.
4.
OtsukiMKasayamaSYamamotoH. Characterization of premature atherosclerosis of carotid arteries in acromegalic patiens. Clin Endocrinol (Oxf). 2001;54(6):791–796.
5.
ColaoASpieziaSCerboneG. Increased arterial intima media thickness by B-M mode echodopler ultrasonography in acromegaly. Clin Endocrinol. 2001;54(4):515–524.
6.
ColaoAMarzulloPLombardiG,. and the Italian Multicenter Study Group on Lantreotide Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol. 2002;146(3):303–309.
7.
GiustinaABarkanACasanueaFF. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85(2):526–529.
8.
BastardJPGrimaldiAJardelCPorquetDBruckertEHainqueB. A simple index of insulin resistance. Diabetes Metab. 1997;23(1):87–88.
9.
PignoliPTremoliEPoliAOrestePPaolettiR. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986;74(6):1399–1406.
10.
TanuguchiAFukushimaMSakaiM. The role of body mass index and trigliceride levels in identifying insulin sensitive and insulin variants in Japanese non-insulin dependent diabetic patients. Metabolism. 2000;49(8):1001–1005.
11.
ColaoAPivonelloRSpieziaS. Persistance of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab. 1999;84(8):2664–2672.
12.
HiraiTSasayamaSKawasakiTYagiS. Stiffness of systemic arteries in patients with myocardial infarction. Circulation. 1989;80(1):78–86.
13.
SesmiloGFairfieldWPKatznelsonK. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-1 levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab. 2002;87(4):1692–1699.
14.
KrsekMPraznyMMarekJSkhraJJustovaVLacinovaZ. The relationship between serum levels of insulin like growth factor-1 and its binding proteins and microvascular function in acromegalic patients. Growth Horm IGF Res. 2002;12(1):54–59.
15.
BrevettiGMarzulloPSilvestroA. Early vascular alterations in acromegaly. J Clin Endocrinol Metab. 2002;87(7):3174–3179.
16.
SmithJCLaneHDaviesN. The effects of depot long acting somatostatin analog on central aortic pressure and arterial stiffness in acromegaly. J Clin Endocrinol Metab. 2003;88(6):2556–2561.
17.
CannavoSAlmotoBCavalliG. Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. J Clin Endocrinol Metab. 2006;91(10): 3766–3772.
18.
BergCPetersennSLahnerH. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab. 2010;95(8):3648–3656.
19.
BogazziFBattollaLSpinelliC. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab. 2007;92(11):4271–4277.
20.
KartalIOflazHPamukçuB. Investigation of early atherosclerotic changes in acromegalic patients. Int J Clin Pract. 2010;64(1):39–44.
21.
TsukaharaHGordienkoDVTonshoffBGelatoMCGoligorskyMS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int. 1994;45(2):598–604.
22.
BögerRHBode-BögerSMMüggeA. Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis. 1995;117(2):273–284.
SalomaaVRileyWKarakJDNardoCFolsomA. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentration are associated with arterial stiffness indexes. Circulation. 1995;91(5):1432–1443.
26.
NapoliRGuardosoleVAngeliniV. Acute effects of growth hormone on vascular function in human subjects. J Clin Endocrinol Metab. 2003;88(6):2817–2820.
27.
NolanBPSenechalPWaqarSMyersJStandleyCAStandleyPR. Altered insulin like growth factor 1 and nitric oxide sensitiveness in hypertension contribute to vascular hyperplasia. Am J Hypertens. 2003;16(5 pt 1):393–400.
28.
JanssenJAMJLStoklRPPolpsHAPGrobeeDELambertsSWJ. Serum total IGF-1, free IGF-1 and IGFBP-1 levels in elderly population to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol. 1998;18(2):277–282.
29.
ClaytonRN. Cardiovascular function in acromegaly. Endocr Rev. 2003;24(3):272–277.
